NF2 Program

About Merlin Therapeutics

Merlin Therapeutics is a private, pre-clinical stage biotech founded in 2021, targeting the rare genetic disorder Neurofibromatosis Type 2 (NF2). The company operates from the biotech hub of Cambridge, MA, and appears to be in an early research and development phase, as indicated by its minimal public-facing website content. Its focused mission on 'every possible cure' suggests an ambitious, potentially platform-based approach to a high-unmet-need oncology and immunology adjacent disorder, though specific pipeline details and leadership are not publicly disclosed.

Therapeutic Areas